TITLE

Controlling the complications of diabetes: It's about the sugar

AUTHOR(S)
Flegel, Ken
PUB. DATE
September 2009
SOURCE
CMAJ: Canadian Medical Association Journal;9/15/2009, Vol. 181 Issue 6/7, p357
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents a reprint of the article "Controlling the Complications of Diabetes: It's About the Sugar," which appeared at www.cmaj.ca. It reflects on the debate whether glucose control is a critical factor to prevent the complications of type 2 diabetes mellitus. However, evidences showed that tight control of glucose levels has been clearly established in type 1 diabetes. He implies that to end this debate is continue learning how best to achieve this therapeutics safely.
ACCESSION #
44132474

 

Related Articles

  • Metformin improves atypical protein kinase C activation by insulin and phosphatidylinositol-3,4,5-(PO4)3 in muscle of diabetic subjects. Luna, V.; Casauban, L.; Sajan, M.; Gomez-Daspet, J.; Powe, J.; Miura, A.; Rivas, J.; Standaert, M.; Farese, R. // Diabetologia;Feb2006, Vol. 49 Issue 2, p375 

    Aims/hypothesis: Metformin is widely used for treating type 2 diabetes mellitus, but its actions are poorly understood. In addition to diminishing hepatic glucose output, metformin, in muscle, activates 5′-AMP-activated protein kinase (AMPK), which alone increases glucose uptake and...

  • EVALUATION OF THE FINNISH DIABETES RISK SCORE (FINDRISC) FOR DIABETES SCREENING IN OCCUPATIONAL HEALTH CARE. MAURICE VANDERSMISSEN, GODELIEVE JOHANNA; GODDERIS, LODE // International Journal of Occupational Medicine & Environmental H;2015, Vol. 28 Issue 3, p587 

    Objectives: The objective of the study was to investigate the prevalence of undiagnosed dysglycaemia and the risk for type 2 diabetes using the Finnish Diabetes Risk Score (FINDRISC) in the working population of Belgium. Moreover, it was to evaluate performance and applicability of FINDRISC as a...

  • DPP-4 Inhibitors as a New Option for the Management of Type 2 Diabetes. Sang Ah Lee // Journal of Korean Diabetes;2013, Vol. 14 Issue 3, p128 

    Dipeptidylpeptidase-4 (DPP-4) inhibitors are new glucose-lowering agents with mechanisms that differ from those of previous oral hypoglycemic agents (OHAs). DPP-4 inhibitors have shown a continuous glucose lowering effect (> 0.5%) when used in monotherapy as well as when used in combination with...

  • Inhibition of SGLT2: A Novel Strategy for Treatment of Type 2 Diabetes Mellitus. Pfister, M.; Whaley, J. M.; Zhang, L.; List, J. F. // Clinical Pharmacology & Therapeutics;Apr2011, Vol. 89 Issue 4, p621 

    The article focuses on the therapeutic use of selective inhibition of sodium-glucose cotransporter 2 (SGLT2) on type 2 diabetes mellitus (T2DM). It discusses the critical roles of SGLT1in the absorption of glucose and galactose and SGLT2 in the mediation of renal glucose reabsorption. Several...

  • Comparison of high fibre diets, basal insulin supplements, and flexible insulin treatment for non-insulin dependent (type II) diabetics poorly controlled with sulphonylureas. Scott, A.R.; Attenborough, Y.; Peacock, I.; Fletcher, E.; Jeffcoate, W.J.; Tattersall, R.B. // BMJ: British Medical Journal (International Edition);9/17/88, Vol. 297 Issue 6650, p707 

    Explores the efficacy of managements for non-insulin-dependent diabetes. Administration of high fiber diet, basal insulin supplements and a regimen of insulin for diabetics; Absence of changes in hemoglobin A[sub 1] concentration during high fiber diet; Improvement of control of diabetes by...

  • Combination Therapy for Type 2 Diabetes. Bell, David S. H. // American Family Physician;12/1/2001, Vol. 64 Issue 11, p1812 

    Editorial. Comments on the combination therapy for type 2 diabetes. Effectiveness of sulfonylurea as treatment for type 2 diabetes; Examination of the insulin therapy; Information on the combined insulin and oral therapy.

  • Pathogenesis of Type 2 Diabetes: Implications for Metformin. DeFronzo, R.A. // Drugs;Dec1999 Supplement 1, Vol. 58 Issue 6, p29 

    Discusses the implications of the pathogenesis of type 2 diabetes for metformin. Insulin resistance in type 2 diabetes mellitus individuals; Defects in insulin action; Information on the initial therapeutic approach in type 2 diabetes mellitus patients.

  • The Antihyperglycaemic Effect of Metformin: Therapeutic and Cellular Mechanisms. Wiernsperger, N.F.; Bailey, C.J. // Drugs;Dec1999 Supplement 1, Vol. 58 Issue 6, p31 

    Metformin is regarded as an antihyperglycaemic agent because it lowers blood glucose concentrations in type 2 (non-insulin-dependent) diabetes without causing overt hypoglycaemia. Its clinical efficacy requires the presence of insulin and involves several therapeutic effects. Of these effects,...

  • Bariatric surgery for obese diabetic subjects.  // Internal Medicine Alert;6/30/2009 Clinical Briefs, p14 

    The article offers findings from a controlled trial in Australia which suggest that surgical therapy can be used as a cost-effective intervention for obesity in type 2 diabetes.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics